Apixaban in Venous Thromboembolism in an Era of New Oral Anticoagulants
MK Turagam, P Velagapudi, N Bongu… - … Current Drug Targets …, 2015 - ingentaconnect.com
Several new oral anticoagulants (NOAC) have been recently studied and approved for the
prevention and treatment of venous thromboembolism (VTE) which includes deep vein …
prevention and treatment of venous thromboembolism (VTE) which includes deep vein …
Apixaban: a review in venous thromboembolism
SL Greig, KP Garnock-Jones - Drugs, 2016 - Springer
Apixaban (Eliquis®) is an oral, direct factor Xa inhibitor that is available for use in the
treatment and secondary prevention of venous thromboembolism (VTE). Like other direct …
treatment and secondary prevention of venous thromboembolism (VTE). Like other direct …
A comprehensive evaluation of apixaban in the treatment of venous thromboembolism
Introduction: The emergence of the direct oral anticoagulants (DOACs) offers patients more
convenient and accessible alternatives to warfarin or parenteral agents for the treatment of …
convenient and accessible alternatives to warfarin or parenteral agents for the treatment of …
Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict
J Carreiro, J Ansell - Expert Opinion on Investigational Drugs, 2008 - Taylor & Francis
For the last half-century, despite its many limitations warfarin has been the mainstay of
treatment for patients with venous and arterial thromboembolic disease. During the past …
treatment for patients with venous and arterial thromboembolic disease. During the past …
Apixaban for extended treatment of venous thromboembolism
Background Apixaban, an oral factor Xa inhibitor that can be administered in a simple, fixed-
dose regimen, may be an option for the extended treatment of venous thromboembolism …
dose regimen, may be an option for the extended treatment of venous thromboembolism …
Apixaban: an emerging oral factor Xa inhibitor
C Roser-Jones, RC Becker - 2010 - Springer
Apixaban, an oral direct factor Xa inhibitor, is currently in late stage clinical development for
the prevention and treatment of thromboembolic diseases. In comparison with current …
the prevention and treatment of thromboembolic diseases. In comparison with current …
Apixaban: a new player in the anticoagulant class
R Agrawal, P Jain, SN Dikshit - Current Drug Targets, 2012 - ingentaconnect.com
Apixaban (BMS-562247-01) is a compound being investigated as an anticoagulant.
Apixaban molecule is developed in a joint venture by Pfizer and Bristol-Myers Squibb …
Apixaban molecule is developed in a joint venture by Pfizer and Bristol-Myers Squibb …
Pharmacodynamics, pharmacokinetics and clinical efficacy of apixaban in the treatment of thrombosis
Introduction: Venous thromboembolism (VTE) is a common disorder. Heparin and vitamin K
antagonists have been the standard treatment for VTE for over 50 years. The development of …
antagonists have been the standard treatment for VTE for over 50 years. The development of …
The role of apixaban for venous and arterial thromboembolic disease
R Prom, SA Spinler - Annals of Pharmacotherapy, 2011 - journals.sagepub.com
Objective: To provide a comprehensive review of the pharmacology, pharmacokinetics,
pharmacodynamics, clinical trial data, adverse effects, and drug interactions of apixaban …
pharmacodynamics, clinical trial data, adverse effects, and drug interactions of apixaban …